Bayer announced in a press release that it has completed its acquisition of Perfuse Therapeutics, Inc, which will now be fully integrated into the company. As previously announced, Bayer has acquired full rights to PER-001, an intravitreal implant that delivers a sustained-release small-molecule endothelin receptor antagonist. The therapy is currently in phase 2 clinical development for the treatment of glaucoma and diabetic retinopathy.

Endothelin signaling has been implicated in vascular constriction, inflammation, and cell death in retinal tissue, with potential relevance to both neurodegenerative and microvascular disease processes.

According to Bayer, the acquisition strengthens the company's pharmaceutical pipeline and aligns with its strategic focus in ophthalmology.

Under the terms of the agreement, Bayer paid an upfront payment of $300 million. The transaction has a potential total value of up to $2.45 billion, including the upfront payment and additional success-based milestone payments, the company said. OM